Ki. Takats et al., The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses, EXP CL E D, 107(1), 1999, pp. 70-74
Citations number
19
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
The objective of the study was to investigate the efficacy of long term thy
rostatic versus radioiodine treatment of hyperthyroidism in old age. Our st
udy is a retrospective analysis of the therapeutical outcome in 66 patients
over 60 years of age with toxic nodular goitre. The patients were divided
in two groups: Group A: 28 patients on methimazole treatment: starting dose
5-30, median (M) 10 mg, maintenance dose 2.5-15 (M = 5) mg, follow up 6 to
240 months (M = 23.5 months). Group B: 38 patients treated by either 100-3
00 MBq (N = 14, subgroup B1) or 325-1000 MBq (N = 24, subgroup B2) I-131, f
ollow up: 18 to 156 months (M = 48 months). The efficacy of the different t
herapeutical approaches were compared by calculating the occurrence rate of
persisting and relapsing thyroid dysfunctions and associated side effects.
The 28 patients on methimazole treatment became euthyroid after 1-16 (M =
5) months bur numerous relapses occurred in the follow up: hyperthyroidism,
clinical: 5, subclinical 13, (relapse duration: M = 8 months; associated s
ymptoms: hypertension in 4, cardiac arrhythmia in 3, cerebral embolism in 1
, angina pectoris in 2, weight loss in 2 cases). Poor patient's compliance
(9/28) or dose reduction by the physician (5/28) were the main causes of th
e relapses. Transient clinical(3 cases) or subclinical (6 cases) hypothyroi
dism also occurred (duration: 1-3 M = 2 months, no clinical symptoms). In 7
out of 14 (50%) patients receiving 100-300 MBq I-131 (Group B1) hyperthyro
idism persisted (versus 4/24-16.7%-in Group B2 following 325-1000 MBq I-131
: chi((1))(2) = 4.78 P = 0.028), methimazole treatment had to be continued
in 9/14 patients (64.3%) (versus 5/24-20.8%- in Group B2.. chi((1))(2) = 7.
18 P = 0.0074) and in 5/14 (35.7%) the radiotherapy had to be repeated (ver
sus 5/24-20.8%-in Group B2, not sign.). Our conclusions are: 1) long term t
hyrostatic treatment is not safe in elderly patients with toxic nodular hyp
erthyroidism, mainly because of poor compliance or dose reduction by the ph
ysician; 2) radioiodine treatment as the first choice should be recommended
for these patients and higher doses should be preferred.